These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22758790)

  • 1. Three-year outcomes of belatacept studies; reason to be optimistic?
    van den Hoogen MW; Pipeleers L
    Am J Transplant; 2012 Aug; 12(8):2259; discussion 2260. PubMed ID: 22758790
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
    Goldfarb DA
    J Urol; 2015 Mar; 193(3):950. PubMed ID: 25765417
    [No Abstract]   [Full Text] [Related]  

  • 3. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.
    Pestana JO; Grinyo JM; Vanrenterghem Y; Becker T; Campistol JM; Florman S; Garcia VD; Kamar N; Lang P; Manfro RC; Massari P; Rial MD; Schnitzler MA; Vitko S; Duan T; Block A; Harler MB; Durrbach A
    Am J Transplant; 2012 Mar; 12(3):630-9. PubMed ID: 22300431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.
    Kirk AD; Guasch A; Xu H; Cheeseman J; Mead SI; Ghali A; Mehta AK; Wu D; Gebel H; Bray R; Horan J; Kean LS; Larsen CP; Pearson TC
    Am J Transplant; 2014 May; 14(5):1142-51. PubMed ID: 24684552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.
    Rostaing L; Vincenti F; Grinyó J; Rice KM; Bresnahan B; Steinberg S; Gang S; Gaite LE; Moal MC; Mondragón-Ramirez GA; Kothari J; Pupim L; Larsen CP
    Am J Transplant; 2013 Nov; 13(11):2875-83. PubMed ID: 24047110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term exposure to belatacept in recipients of extended criteria donor kidneys.
    Charpentier B; Medina Pestana JO; Del C Rial M; Rostaing L; Grinyó J; Vanrenterghem Y; Matas A; Zhang R; Mühlbacher F; Pupim L; Florman S
    Am J Transplant; 2013 Nov; 13(11):2884-91. PubMed ID: 24103072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Belatacept: a novel immunosuppressive agent for kidney transplant recipients.
    Charpentier B
    Expert Rev Clin Immunol; 2012 Nov; 8(8):719-28. PubMed ID: 23167683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belatacept (Nulojix) for prevention of renal transplant rejection.
    Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):98-9. PubMed ID: 22173428
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients.
    Koppula S; Yost SE; Sussman A; Bracamonte ER; Kaplan B
    Clin Transplant; 2013; 27(4):591-7. PubMed ID: 23923969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kidney transplant recipients treated with belatacept exhibit increased naïve and transitional B cells.
    Leibler C; Matignon M; Pilon C; Montespan F; Bigot J; Lang P; Carosella ED; Cohen J; Rouas-Freiss N; Grimbert P; Menier C
    Am J Transplant; 2014 May; 14(5):1173-82. PubMed ID: 24730563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Belatacept.
    Vincenti F; Dritselis A; Kirkpatrick P
    Nat Rev Drug Discov; 2011 Aug; 10(9):655-6. PubMed ID: 21878974
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
    Wen X; Casey MJ; Santos AH; Hartzema A; Womer KL
    Am J Transplant; 2016 Nov; 16(11):3202-3211. PubMed ID: 27137884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4-weekly or 8-weekly.
    Vincenti F; Blancho G; Durrbach A; Grannas G; Grinyó J; Meier-Kriesche HU; Polinsky M; Yang L; Larsen CP
    Am J Transplant; 2017 Dec; 17(12):3219-3227. PubMed ID: 28758341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological agents in kidney transplantation: belatacept is entering the field.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Expert Opin Biol Ther; 2010 Oct; 10(10):1501-8. PubMed ID: 20726688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Belatacept: the promises and challenges of belatacept and costimulatory blockade.
    Kaplan B
    Am J Transplant; 2010 Mar; 10(3):441-2. PubMed ID: 20415895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study.
    Bertrand D; Cheddani L; Etienne I; François A; Hanoy M; Laurent C; Lebourg L; Le Roy F; Lelandais L; Loron MC; Godin M; Guerrot D
    Am J Transplant; 2017 Nov; 17(11):2937-2944. PubMed ID: 28707779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond belatacept: praise and progress for the FDA.
    Vincenti F
    Am J Transplant; 2012 Mar; 12(3):513-4. PubMed ID: 22335245
    [No Abstract]   [Full Text] [Related]  

  • 19. Rationale for using belatacept in combination with sirolimus.
    Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L
    Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion to belatacept-based immunosuppression therapy in renal transplant patients.
    Paz M; Roberti J; Mos F; Cicora F
    Transplant Proc; 2014 Nov; 46(9):2987-90. PubMed ID: 25420807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.